GI STACK
Next-Generation
Formula
Precision support for gut integrity, barrier function, and digestive resilience
Highest Quality Raw Product Sourcing
Rigorous Third Party Testing
Comprehensive Recovery Benefits
Think of GI Stack as a three-part tactical approach: (1) repair the lining, (2) calm inflammatory signaling, and (3) reduce paracellular leakiness — all from an oral, stable formulation designed to be compatible with everyday use and clinical practice.
Repair the Lining
BPC-157 Arginate supports mucosal epithelial restitution and accelerates healing in animal models
Calm Inflammation
KPV tripeptide reduces inflammatory cytokine expression and protects epithelial cells.
Reduce Leakiness
Larazotide modulates tight junctions and reduces paracellular permeability.
What is the GI Stack?
Three research-backed compounds working in synergy
BPC-157 Arginate
A 15-amino-acid molecule studied extensively in preclinical models for mucosal and tissue protection and repair. Studies report protective effects across gastric, intestinal and vascular tissues and interactions with angiogenesis and the nitric-oxide system.
- Stimulates mucosal restitution and epithelial healing
- Modulates NO system and vasomotor tone
- Demonstrates stability in gastric juice after oral administration
KPV (Lys-Pro-Val)
KPV is taken up via intestinal transporters (PepT1) and has shown meaningful reduction of cytokine-driven inflammation in preclinical colitis models.
- Reduces mucosal cytokines and neutrophil influx
- Uptake via PepT1 provides targeted intestinal delivery
- Protects epithelial cells from inflammatory injury
Larazotide
A small molecule that modulates epithelial tight-junctions and has been studied in multiple clinical trials for reduction of intestinal permeability and symptomatic benefit in gluten challenge / celiac contexts.
Multiple randomized trials with favorable safety profiles
Reduces gluten-induced symptoms and immune reactivity
Ongoing phase trials as adjunct to dietary therapy
WHY CHOOSE BIOTHRIVE
- Clinician owned, Operated and Curated Product line
- Highest Quality Raw Product Sourcing
- Rigorous Third Party Testing
Science-Backed Research
Extensive research in animal models and patient case studies demonstrates the potential of BPC-157 and TB4 Fragment combination.
Preclinical Evidence
Extensive preclinical literature demonstrates mucosal protection, repair, and anti-inflammatory effects across multiple animal models and cell systems.
Clinical Trials
Larazotide has established safety and tolerability records through multiple randomized clinical trials in celiac disease contexts.
Mechanistic Rationale
Each compound addresses complementary aspects: barrier reinforcement, epithelial repair, and inflammation modulation.
Safety & Regulatory Framing
Not FDA-approved: None of the molecules in GI Stack are FDA-approved as a treatment for specific diseases. Claims on this page are framed to reflect primarily preclinical and early clinical evidence.
Safety signals: Larazotide has an established record of tolerability in clinical trials. BPC-157 and KPV have robust preclinical safety datasets but limited controlled human safety trials; therefore users and clinicians must take a cautious, evidence-based approach.
Clinical use: GI Stack is formulated for research-minded consumers and clinicians who appreciate mechanistic rationale. It is not a replacement for medical therapy; clinicians may consider it as an adjunct in carefully selected, monitored patients or in research contexts.
What Our Customers Say
We believe in the transformative potential of these powerful compound and their ability to revolutionize how we approach recovery and performance enhancement.